Cystic Fibrosis Clinical Trial
Official title:
CFfone: A Cell Phone Support Program for Adolescents With Cystic Fibrosis
Adolescents with cystic fibrosis are particularly vulnerable to poor adherence, which negatively impacts their health status, quality of life and long term survival. CFFONE: A Cell Phone Support Program for Adolescents with Cystic Fibrosis, will make use of cutting-edge technology- a broadband capable, cellular telephone keyed into a highly-interactive informational web site. This web site will provide engaging online learning activities and resources specific to adolescents with cystic fibrosis. We believe the information and activities contained in CFFONE will improve adolescents knowledge, attitudes, and practices around cystic fibrosis and that adolescents exposed to the CFFONE program will demonstrate an increase in adherence to their treatment regimens and related improvements in their health status and quality of life.
Generations of patients with cystic fibrosis (CF) have spent their childhoods fighting for
breath and losing. Until recently, CF patients succumbed to this fatal, inherited lung
disease as infants, young children or adolescents. With cutting-edge research spurring
medical advances, each decade has shown improved survival, from a median life expectancy of
5 years in 1960, to 16 years in 1970, to 35 years today. Yet, the disease remains complex
and adolescents with CF experience challenges that can reduce their adherence to treatment
regimens and undermine their long-term well-being.
Poor adherence to complicated life long treatments impacts a patient's health and burdens
the medical system. Adolescents are particularly vulnerable to poor adherence and its high
costs. Even adolescents who experience comparatively mild symptoms of CF must follow a
3-hour treatment regimen every day, and medical experts report that their adherence ranges
from poor (50% doing less than prescribed airway clearance regimen) to very poor (30% not
doing any prescribed treatments).
CF can cause a host of social-emotional stressors, including uncertainty about the future,
poor self-image, low self-esteem, and frustration with delayed growth/maturation all of
which can impede adherence. Absences from school, being teased, keeping their illness
secret, and lack of access to peers with CF due to risk of infection leave many adolescents
with CF feeling isolated and alone. Due to parent over-protection and medical services that
focus on symptoms, these patients often lack supportive coaching on issues (e.g.,
alcohol-and tobacco-related risks, sexual health, infection control, pain control, career
prospects) that can impact the quality of their life.
This Phase II Randomized Control Trial (study) will test the hypothesis that adolescents
with cystic fibrosis (CF) ages 11-17 (adolescent participants) and young adults with CF,
ages 18-20 (adult participants) who access a password-protected, secure mobile website
(CFFONE), via a web capable cell phone and use the site's age appropriate medical and
behavioral information, disease management tools and social networking features will
demonstrate: (1) an increase in CF knowledge- the primary end point of the study; (2)
improved treatment adherence and improved quality of life- the secondary end points of the
study and; (3) enhanced social support- the exploratory end point of the study, when
compared to control group adolescent participants and adult participants.
To test this hypothesis, a longitudinal experimental design will be carried out in which
participants will be randomly assigned to one of two conditions: cell phone access to
CFFONE; or registering with a CF-related educational website containing CF information and
services relevant to adolescents.
A recent National Institutes for Health solicitation for research to improve self-management
and quality of life in children and adolescents with chronic diseases stated that, "Children
with a chronic disease face a lifetime of careful health management requirements and
lifestyle adaptations to prevent or manage related health complications. Interventions that
make a difference in childhood disease self-management may set the stage for health outcomes
later in life." (2003) We believe that CFFONE, with its innovative approach for enhancing
self-management, has the potential to make that kind of difference in the lives of
adolescents with cystic fibrosis.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04696198 -
Thoracic Mobility in Cystic Fibrosis Care
|
N/A | |
Completed |
NCT00803205 -
Study of Ataluren (PTC124™) in Cystic Fibrosis
|
Phase 3 | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03601637 -
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
|
Phase 3 | |
Terminated |
NCT02769637 -
Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
|
||
Recruiting |
NCT06030206 -
Lung Transplant READY CF 2: A Multi-site RCT
|
N/A | |
Recruiting |
NCT06012084 -
The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis
|
N/A | |
Recruiting |
NCT06032273 -
Lung Transplant READY CF 2: CARING CF Ancillary RCT
|
N/A | |
Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
Recruiting |
NCT05392855 -
Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)
|
N/A | |
Recruiting |
NCT04039087 -
Sildenafil Exercise: Role of PDE5 Inhibition
|
Phase 2/Phase 3 | |
Recruiting |
NCT04056702 -
Impact of Triple Combination CFTR Therapy on Sinus Disease.
|
||
Completed |
NCT04038710 -
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
|
||
Completed |
NCT04058548 -
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
|
N/A | |
Completed |
NCT03637504 -
Feasibility of a Mobile Medication Plan Application in CF Patient Care
|
N/A | |
Recruiting |
NCT03506061 -
Trikafta in Cystic Fibrosis Patients
|
Phase 2 | |
Completed |
NCT03566550 -
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
|
||
Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
Recruiting |
NCT04010253 -
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
|
N/A |